Home Applications 216490 Application 216490
Type NDA
Sponsor ASCENDIS PHARMA BONE Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 YORVIPATH PALOPEGTERIPARATIDE SOLUTION;SUBCUTANEOUS EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) Yes Yes 002 YORVIPATH PALOPEGTERIPARATIDE SOLUTION;SUBCUTANEOUS EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) Yes No 003 YORVIPATH PALOPEGTERIPARATIDE SOLUTION;SUBCUTANEOUS EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N216490-001 YORVIPATH PALOPEGTERIPARATIDE EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 N216490-002 YORVIPATH PALOPEGTERIPARATIDE EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 N216490-003 YORVIPATH PALOPEGTERIPARATIDE EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09
Orange Book patents# Current patent rows page 1 of 1 · 27 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N216490-001 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 N216490-001 11590207 2037-09-28 U-3982 2024-09-05 N216490-001 11759504 2037-09-28 Drug product 2024-09-05 N216490-001 11857603 2037-09-28 U-3982 2024-09-05 N216490-001 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-001 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-001 12295989 2037-09-28 U-3982 2025-05-29 N216490-001 12453778 2037-09-28 U-3982 2025-11-12 N216490-001 12403182 2042-11-12 U-3982 Drug product 2025-09-05 N216490-002 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 N216490-002 11590207 2037-09-28 U-3982 2024-09-05 N216490-002 11759504 2037-09-28 Drug product 2024-09-05 N216490-002 11857603 2037-09-28 U-3982 2024-09-05 N216490-002 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-002 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-002 12295989 2037-09-28 U-3982 2025-05-29 N216490-002 12453778 2037-09-28 U-3982 2025-11-12 N216490-002 12403182 2042-11-12 U-3982 Drug product 2025-09-05 N216490-003 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 N216490-003 11590207 2037-09-28 U-3982 2024-09-05 N216490-003 11759504 2037-09-28 Drug product 2024-09-05 N216490-003 11857603 2037-09-28 U-3982 2024-09-05 N216490-003 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-003 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-003 12295989 2037-09-28 U-3982 2025-05-29 N216490-003 12453778 2037-09-28 U-3982 2025-11-12 N216490-003 12403182 2042-11-12 U-3982 Drug product 2025-09-05
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 6 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 45 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2024-10-29 15:01 UTC 2024-10 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 d06236e962d9…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 8 · 318 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N216490-001 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 11590207 2037-09-28 U-3982 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 11759504 2037-09-28 Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 11857603 2037-09-28 U-3982 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 12295989 2037-09-28 U-3982 2025-05-29 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 12453778 2037-09-28 U-3982 2025-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-001 12403182 2042-11-12 U-3982 Drug product 2025-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 11590207 2037-09-28 U-3982 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 11759504 2037-09-28 Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 11857603 2037-09-28 U-3982 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 12295989 2037-09-28 U-3982 2025-05-29 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 12453778 2037-09-28 U-3982 2025-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-002 12403182 2042-11-12 U-3982 Drug product 2025-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 11590207 2037-09-28 U-3982 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 11759504 2037-09-28 Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 11857603 2037-09-28 U-3982 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 12295989 2037-09-28 U-3982 2025-05-29 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 12453778 2037-09-28 U-3982 2025-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N216490-003 12403182 2042-11-12 U-3982 Drug product 2025-09-05 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N216490-001 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 11590207 2037-09-28 U-3982 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 11759504 2037-09-28 Drug product 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 11857603 2037-09-28 U-3982 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 12295989 2037-09-28 U-3982 2025-05-29 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 12453778 2037-09-28 U-3982 2025-11-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-001 12403182 2042-11-12 U-3982 Drug product 2025-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-002 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-002 11590207 2037-09-28 U-3982 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-002 11759504 2037-09-28 Drug product 2024-09-05 c2088c7a36db…2026-10-15 13:18:30 2026-09 N216490-002 11857603 2037-09-28 U-3982 2024-09-05 c2088c7a36db…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 3 · 87 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Yorvipath PALOPEGTERIPARATIDE Ascendis Pharma, Endocrinology, Inc. a1fa23fd-c434-443e-9a17-5750578c8602 2026-11-03 Warnings, Adverse reactions Exact identifier application applno (NDA): 216490 application number: NDA216490
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 83846 SUPPL 2025-10-21 83804 SUPPL 2025-10-20 83803 SUPPL 2025-10-20 79565 ORIG 2024-10-15 79375 ORIG 2024-08-12 79370 ORIG 2024-08-12